You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
Kedrion Biosc - Front Image


  1. 27-06-2017

    Cash Tender Offer for Notes due 24 April 2019

    Tender Offer for €300,000,000 4.625 per cent. Notes due 24 April 2019

    read more 
  2. 27-04-2017

    Audited financial statements 2016

    Kedrion’s shareholders meeting approved the 2016 stand-alone Financial Statements and acknowledged the 2016 Consolidated FS

    read more 
  3. 31-03-2017

    Annual Results 2016

    Consolidated turnover of 659.3 million Euro, a growth of 89 million Euro or 15.6%

    read more 
  4. 19-01-2016

    Kedrion Biopharma strengthens its position on the US market

    Granted exclusive rights to commercialize a lifesaving drug in the US

    read more 
  5. 29-09-2015

    Kedrion Notes 2019 Tender Offer results

    Kedrion has decided to accept for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000

    read more 
  6. 21-09-2015

    Cash Tender Offer for Notes due 24 April 2019

    Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019.

    read more 
  7. 26-11-2014

    Kedrion receives the “VedoGreen, Green Excellence in Innovation” Award

    The awards ceremony held in Milan on November 17, during Waiting for Expo 2015, Green Economy 2.0

    read more 
  8. 12-11-2014

    Kedrion joins the programme “ELITE for Large Corporates”

    Launched by Borsa Italiana, ELITE is targeted to companies aiming at strengthening their global leadership

    read more 
  9. 15-10-2014

    New generation immunoglobulins: in January production of clinical batches

    The first batch for the feasibility test was produced at the Gödöllő plant in September with results in compliance with specifications

    read more 
  10. 08-09-2014

    Kedrion’s key financials and milestones in the new Investor Relations area

    Website area dedicated to providing the financial community with latest information regarding the Kedrion Bond

    read more 


For more information please contact: